{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:06:50Z","timestamp":1790996810833,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,5,13]],"date-time":"2011-05-13T00:00:00Z","timestamp":1305244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2011,5,13]],"date-time":"2011-05-13T00:00:00Z","timestamp":1305244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (<jats:italic>n<\/jats:italic> = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar3337","type":"journal-article","created":{"date-parts":[[2011,5,13]],"date-time":"2011-05-13T18:35:01Z","timestamp":1305311701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":180,"title":["Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)"],"prefix":"10.1186","volume":"13","author":[{"given":"Hans-Peter","family":"Tony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Grunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonore","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svjetlana","family":"Lovric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Haubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fischer-Betz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Chehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Specker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Weinerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Holle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Burgwinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"S\u00f6rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Meurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Erfurt-Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Strutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praxis","family":"von Wussow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian MP","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Hunzelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Bergner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Eming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwarz-Eywill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Wassenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waltraud","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Freivogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GRAID investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,13]]},"reference":[{"key":"3107_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00002281-200305000-00011","volume":"15","author":"T D\u00f6rner","year":"2003","unstructured":"D\u00f6rner T, Burmester GR: The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol. 2003, 15: 246-252. 10.1097\/00002281-200305000-00011.","journal-title":"Curr Opin Rheumatol"},{"key":"3107_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nri1838","volume":"6","author":"JC Edwards","year":"2006","unstructured":"Edwards JC, Cambridge G: B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006, 6: 394-403. 10.1038\/nri1838.","journal-title":"Nat Rev Immunol"},{"key":"3107_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nrrheum.2010.68","volume":"6","author":"I Sanz","year":"2010","unstructured":"Sanz I, Lee FE: B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010, 6: 326-337. 10.1038\/nrrheum.2010.68.","journal-title":"Nat Rev Rheumatol"},{"key":"3107_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrrheum.2009.141","volume":"5","author":"T D\u00f6rner","year":"2009","unstructured":"D\u00f6rner T, Radbruch A, Burmester GR: B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009, 5: 433-441. 10.1038\/nrrheum.2009.141.","journal-title":"Nat Rev Rheumatol"},{"key":"3107_CR5","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.10947","volume":"48","author":"GJ Silverman","year":"2003","unstructured":"Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003, 48: 1484-1492. 10.1002\/art.10947.","journal-title":"Arthritis Rheum"},{"key":"3107_CR6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaci.2010.02.025","volume":"125","author":"S Lee","year":"2010","unstructured":"Lee S, Ballow M: Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. J Allergy Clin Immunol. 2010, 125: 814-820. 10.1016\/j.jaci.2010.02.025.","journal-title":"J Allergy Clin Immunol"},{"key":"3107_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","volume":"9","author":"T D\u00f6rner","year":"2009","unstructured":"D\u00f6rner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G: International Roundtable on B cells as Therapeutic Target for Intervention: Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev. 2009, 9: 82-10.1016\/j.autrev.2009.08.007.","journal-title":"Autoimmun Rev"},{"key":"3107_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010, 363: 211-220. 10.1056\/NEJMoa0909169.","journal-title":"N Engl J Med"},{"key":"3107_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363: 221-232. 10.1056\/NEJMoa0909905.","journal-title":"N Engl J Med"},{"key":"3107_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJMe1004992","volume":"363","author":"RJ Falk","year":"2010","unstructured":"Falk RJ, Jennette JC: Rituximab in ANCA-associated disease. N Engl J Med. 2010, 363: 285-286. 10.1056\/NEJMe1004992.","journal-title":"N Engl J Med"},{"key":"3107_CR11","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54: 2793-2806. 10.1002\/art.22025.","journal-title":"Arthritis Rheum"},{"key":"3107_CR12","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004, 350: 2572-2581. 10.1056\/NEJMoa032534.","journal-title":"N Engl J Med"},{"key":"3107_CR13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006, 54: 1390-1400. 10.1002\/art.21778.","journal-title":"Arthritis Rheum"},{"key":"3107_CR14","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biologic-naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010, 69: 1629-1635. 10.1136\/ard.2009.119933.","journal-title":"Ann Rheum Dis"},{"key":"3107_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3899\/jrheum.090442","volume":"37","author":"PJ Mease","year":"2010","unstructured":"Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A: Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010, 37: 917-927. 10.3899\/jrheum.090442.","journal-title":"J Rheumatol"},{"key":"3107_CR16","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","volume":"49","author":"A Rubbert-Roth","year":"2010","unstructured":"Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carre\u00f1o L, Armstrong G, Collinson N, Shaw TM, MIRROR Trial Investigators: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010, 49: 1683-1693. 10.1093\/rheumatology\/keq116.","journal-title":"Rheumatology (Oxford)"},{"key":"3107_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"RF van Vollenhoven","year":"2010","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R: Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheum. 2010, 37: 558-567. 10.3899\/jrheum.090856.","journal-title":"J Rheum"},{"key":"3107_CR18","first-page":"566","volume":"11","author":"N Avshovich","year":"2009","unstructured":"Avshovich N, Boulman N, Slobodin G, Zeina AR, Rosner I, Rozenbaum M: Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement. Isr Med Assoc J. 2009, 11: 566-568.","journal-title":"Isr Med Assoc J"},{"key":"3107_CR19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/ICO.0b013e3181c296ed","volume":"29","author":"V Huerva","year":"2010","unstructured":"Huerva V, Sanchez MC, Traveset A, Jurjo C, Ruiz A: Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis. Cornea. 2010, 29: 708-710.","journal-title":"Cornea"},{"key":"3107_CR20","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009, 60: 2156-2168. 10.1002\/art.24637.","journal-title":"Arthritis Rheum"},{"key":"3107_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/art.20718","volume":"52","author":"KA Keogh","year":"2005","unstructured":"Keogh KA, Wylam ME, Stone JH, Specks U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005, 52: 262-268. 10.1002\/art.20718.","journal-title":"Arthritis Rheum"},{"key":"3107_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","volume":"173","author":"KA Keogh","year":"2006","unstructured":"Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006, 173: 180-187.","journal-title":"Am J Respir Crit Care Med"},{"key":"3107_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","volume":"34","author":"M Martinez Del Pero","year":"2009","unstructured":"Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D: B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol. 2009, 34: 328-335. 10.1111\/j.1749-4486.2009.01968.x.","journal-title":"Clin Otolaryngol"},{"key":"3107_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/RHU.0b013e3181886064","volume":"14","author":"AM Patel","year":"2008","unstructured":"Patel AM, Lehman TJ: Rituximab for severe refractory pediatric Wegener granulomatosis. J Clin Rheumatol. 2008, 14: 278-280. 10.1097\/RHU.0b013e3181886064.","journal-title":"J Clin Rheumatol"},{"key":"3107_CR25","first-page":"2017","volume":"35","author":"P Seo","year":"2008","unstructured":"Seo P, Specks U, Keogh KA: Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol. 2008, 35: 2017-2023.","journal-title":"J Rheumatol"},{"key":"3107_CR26","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","volume":"44","author":"U Specks","year":"2001","unstructured":"Specks U, Fervenza FC, McDonald TJ, Hogan MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001, 44: 2836-2840. 10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W.","journal-title":"Arthritis Rheum"},{"key":"3107_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.tripleo.2009.02.025","volume":"108","author":"KS Staines","year":"2009","unstructured":"Staines KS, Higgins B: Recurrence of Wegener's granulomatosis with de novo intraoral presentation treated successfully with rituximab. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009, 108: 76-80. 10.1016\/j.tripleo.2009.02.025.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"3107_CR28","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24454","volume":"60","author":"SR Taylor","year":"2009","unstructured":"Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL: Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009, 60: 1540-1547. 10.1002\/art.24454.","journal-title":"Arthritis Rheum"},{"key":"3107_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ndt\/gfn430","volume":"24","author":"S Lovric","year":"2009","unstructured":"Lovric S, Erdbruegger U, K\u00fcmpers P, Woywodt A, Koenecke C, Wedemeyer H, Haller H, Haubitz M: Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody associated vasculitis: single centre experience with fifteen patients. Nephrol Dial Transplant. 2009, 24: 179-185.","journal-title":"Nephrol Dial Transplant"},{"key":"3107_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","volume":"357","author":"P Joly","year":"2007","unstructured":"Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P: A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007, 357: 545-552. 10.1056\/NEJMoa067752.","journal-title":"N Engl J Med"},{"key":"3107_CR31","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","volume":"355","author":"AR Ahmed","year":"2006","unstructured":"Ahmed AR, Spigelman Z, Cavacini LA, Posner MR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006, 355: 1772-1779. 10.1056\/NEJMoa062930.","journal-title":"N Engl J Med"},{"key":"3107_CR32","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1038\/jid.2009.27","volume":"129","author":"A Nagel","year":"2009","unstructured":"Nagel A, Podstawa E, Eickmann M, M\u00fcller HH, Hertl M, Eming R: Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 2009, 129: 2202-2210. 10.1038\/jid.2009.27.","journal-title":"J Invest Dermatol"},{"key":"3107_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","volume":"1173","author":"E Schmidt","year":"2009","unstructured":"Schmidt E, Goebeler M, Zillikens D: Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009, 1173: 683-691. 10.1111\/j.1749-6632.2009.04744.x.","journal-title":"Ann N Y Acad Sci"},{"key":"3107_CR34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","volume":"45","author":"L Quartuccio","year":"2006","unstructured":"Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S: Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology. 2006, 45: 842-846. 10.1093\/rheumatology\/kel004.","journal-title":"Rheumatology"},{"key":"3107_CR35","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003, 101: 3827-3834. 10.1182\/blood-2002-09-2856.","journal-title":"Blood"},{"key":"3107_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005, 52: 601-607. 10.1002\/art.20849.","journal-title":"Arthritis Rheum"},{"key":"3107_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/art.10764","volume":"48","author":"JH Anolik","year":"2003","unstructured":"Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003, 48: 455-459. 10.1002\/art.10764.","journal-title":"Arthritis Rheum"},{"key":"3107_CR38","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","volume":"56","author":"JH Anolik","year":"2007","unstructured":"Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I: Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007, 56: 3044-3056. 10.1002\/art.22810.","journal-title":"Arthritis Rheum"},{"key":"3107_CR39","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/ard.2007.079418","volume":"67","author":"G Cambridge","year":"2008","unstructured":"Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W: B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis. 2008, 67: 1011-1016.","journal-title":"Ann Rheum Dis"},{"key":"3107_CR40","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","volume":"25","author":"F Catapano","year":"2010","unstructured":"Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW: Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010, 25: 3586-3592. 10.1093\/ndt\/gfq256.","journal-title":"Nephrol Dial Transplant"},{"key":"3107_CR41","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1002\/art.10541","volume":"46","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002, 46: 2673-2677. 10.1002\/art.10541.","journal-title":"Arthritis Rheum"},{"key":"3107_CR42","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","volume":"44","author":"MJ Leandro","year":"2005","unstructured":"Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005, 44: 1542-1545. 10.1093\/rheumatology\/kei080.","journal-title":"Rheumatology (Oxford)"},{"key":"3107_CR43","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 2004, 50: 2580-2589. 10.1002\/art.20430.","journal-title":"Arthritis Rheum"},{"key":"3107_CR44","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/art.24341","volume":"61","author":"TY Lu","year":"2009","unstructured":"Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA: A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009, 61: 482-487. 10.1002\/art.24341.","journal-title":"Arthritis Rheum"},{"key":"3107_CR45","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/ard.2006.067124","volume":"66","author":"KP Ng","year":"2007","unstructured":"Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA: B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis. 2007, 66: 1259-1262. 10.1136\/ard.2006.067124.","journal-title":"Ann Rheum Dis"},{"key":"3107_CR46","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/ard.2005.044420","volume":"65","author":"PM Aries","year":"2006","unstructured":"Aries PM, Hellmich B, Voswinkel J, Both M, N\u00f6lle B, Holl-Ulrich K, Lamprecht P, Gross WL: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2006, 65: 853-858.","journal-title":"Ann Rheum Dis"},{"key":"3107_CR47","first-page":"S23","volume":"25","author":"B Brihaye","year":"2007","unstructured":"Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L: Adjunction of rituximab to steroids and immunosuppressants for refractory\/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol. 2007, 25: S23-S27.","journal-title":"Clin Exp Rheumatol"},{"key":"3107_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/02813430510015269","volume":"34","author":"R Omdal","year":"2005","unstructured":"Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G: Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol. 2005, 34: 229-232. 10.1080\/02813430510015269.","journal-title":"Scand J Rheumatol"},{"key":"3107_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2169\/internalmedicine.46.6156","volume":"46","author":"N Tamura","year":"2007","unstructured":"Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, Morimoto S, Kaneda K, Kobayashi S, Hashimoto H, Takasaki Y: Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med. 2007, 46: 409-414. 10.2169\/internalmedicine.46.6156.","journal-title":"Intern Med"},{"key":"3107_CR50","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/rheumatology\/kel387","volume":"46","author":"H Cohen","year":"2007","unstructured":"Cohen H, Green S, Jones S, Amos N, William BD: Lack of efficacy of rituximab in a patient with essential mixed cryoglobulinaemia. Rheumatology (Oxford). 2007, 46: 366-367.","journal-title":"Rheumatology (Oxford)"},{"key":"3107_CR51","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007, 143: 763-767. 10.1001\/archderm.143.6.763.","journal-title":"Arch Dermatol"},{"key":"3107_CR52","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/art.27383","volume":"62","author":"IH Song","year":"2010","unstructured":"Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J: Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010, 62: 1290-1297. 10.1002\/art.27383.","journal-title":"Arthritis Rheum"},{"key":"3107_CR53","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jbspin.2008.01.023","volume":"75","author":"D Wendling","year":"2008","unstructured":"Wendling D, Aug\u00e9 B, Streit G, Toussirot E, Mathieu S: Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine. 2008, 75: 510-511. 10.1016\/j.jbspin.2008.01.023.","journal-title":"Joint Bone Spine"},{"key":"3107_CR54","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1002\/art.25000","volume":"60","author":"D S\u00e8ne","year":"2009","unstructured":"S\u00e8ne D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P: Rituximab may form a complex with IgM kappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009, 60: 3848-3855. 10.1002\/art.25000.","journal-title":"Arthritis Rheum"},{"key":"3107_CR55","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK: Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005, 62: 258-264. 10.1001\/archneur.62.2.258.","journal-title":"Arch Neurol"},{"key":"3107_CR56","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008, 358: 676-688. 10.1056\/NEJMoa0706383.","journal-title":"N Engl J Med"},{"key":"3107_CR57","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS trial group: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009, 66: 460-471. 10.1002\/ana.21867.","journal-title":"Ann Neurol"},{"issue":"Suppl 10","key":"3107_CR58","first-page":"1149","volume":"60","author":"R Furie","year":"2009","unstructured":"Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, Fervenza FC, Maciuca R, Brunetta P, Zhang D, Garg J: Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009, 60 (Suppl 10): 1149-","journal-title":"Arthritis Rheum"},{"key":"3107_CR59","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010, 62: 222-233. 10.1002\/art.27233.","journal-title":"Arthritis Rheum"},{"key":"3107_CR60","first-page":"468","volume":"28","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Garcia-Hernandez FJ, De Ramon E, Callejas JL, Martinez-Berriotxoa A, Pallares L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Perez-Alvarez R, Mico ML, Medrano F, Gomez de la Torre R, Diaz-Lagares C, Camps MT, Ortego N, Sanchez-Roman J: Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010, 28: 468-476.","journal-title":"Clin Exp Rheumatol"},{"key":"3107_CR61","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1002\/art.27541","volume":"62","author":"B Terrier","year":"2010","unstructured":"Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harl\u00e9 JR, Hot A, Kahn JE, Lambotte O, Larroche C, L\u00e9one J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, et al: Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010, 62: 2458-2466. 10.1002\/art.27541.","journal-title":"Arthritis Rheum"},{"key":"3107_CR62","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrrheum.2010.83","volume":"6","author":"PE Lipsky","year":"2010","unstructured":"Lipsky PE, D\u00f6rner T: The red wolf remains a wily foe. Nat Rev Rheumatol. 2010, 6: 307-308. 10.1038\/nrrheum.2010.83.","journal-title":"Nat Rev Rheumatol"},{"key":"3107_CR63","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Lo\u00ebt X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X, AutoImmunity and Rituximab Registry and French Society of Rheumatology: Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010, 62: 2625-2632. 10.1002\/art.27555.","journal-title":"Arthritis Rheum"},{"key":"3107_CR64","first-page":"1473","volume":"32","author":"T Gl\u00fcck","year":"2005","unstructured":"Gl\u00fcck T, Kiefmann B, Grohmann M, Falk W, Straub RH, Sch\u00f6lmerich J: Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol. 2005, 32: 1473-1480.","journal-title":"J Rheumatol"},{"issue":"Suppl 3","key":"3107_CR65","first-page":"382","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, M\u00fcller-Ladner U, Gaylis N, Williams S, Tyrell H, Reynard M: Retreatment with rituximab based on a treatment to target approach provides better disease control than treatment as needed in patients with RA [abstract]. Ann Rheum Dis. 2010, 69 (Suppl 3): 382-","journal-title":"Ann Rheum Dis"},{"key":"3107_CR66","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/ard.2008.100438","volume":"68","author":"YK Teng","year":"2009","unstructured":"Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JW, van Laar JM: Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis. 2009, 68: 1075-1077. 10.1136\/ard.2008.100438.","journal-title":"Ann Rheum Dis"},{"key":"3107_CR67","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10067-005-1164-z","volume":"25","author":"A Airio","year":"2006","unstructured":"Airio A, Kautiainen H, Hakala M: Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006, 25: 234-239. 10.1007\/s10067-005-1164-z.","journal-title":"Clin Rheumatol"},{"key":"3107_CR68","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/ard.2008.088302","volume":"68","author":"C Charlier","year":"2009","unstructured":"Charlier C, Henegar C, Launay O, Pagnoux C, Berezn\u00e9 A, Bienvenu B, Cohen P, Mouthon L, Guillevin L: Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009, 68: 658-663. 10.1136\/ard.2008.088302.","journal-title":"Ann Rheum Dis"},{"key":"3107_CR69","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1001\/archdermatol.2009.152","volume":"145","author":"L Fardet","year":"2009","unstructured":"Fardet L, Rybojad M, Gain M, Kettaneh A, Cherin P, Bachelez H, Dubertret L, Lebbe C, Morel P, Dupuy A: Incidence, risk factors, and severity of herpes virus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol. 2009, 145: 889-893. 10.1001\/archdermatol.2009.152.","journal-title":"Arch Dermatol"},{"key":"3107_CR70","first-page":"S94","volume":"26","author":"R Phillip","year":"2008","unstructured":"Phillip R, Luqmani R: Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008, 26: S94-S104.","journal-title":"Clin Exp Rheumatol"},{"key":"3107_CR71","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.25080","volume":"127","author":"KG Sunesen","year":"2010","unstructured":"Sunesen KG, N\u00f8rgaard M, Thorlacius-Ussing O, Laurberg S: Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer. 2010, 127: 675-684. 10.1002\/ijc.25080.","journal-title":"Int J Cancer"},{"key":"3107_CR72","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG, Jones RB, Burns SM, Jayne DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006, 54: 2970-2982. 10.1002\/art.22046.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar3337\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:04:35Z","timestamp":1728385475000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,13]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,6]]}},"alternative-id":["3107"],"URL":"https:\/\/doi.org\/10.1186\/ar3337","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,13]]},"assertion":[{"value":"1 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R75"}}